None of the 29 investors followed here reported a position in YARW in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a YARW trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| May 28, 2026 | Domzalski David TChief Executive Officer | Stock Award(Grant) at price 0.31 per share. | 30.8K | $9.54K |
| Jun 1, 2025 | Harsch Mutya FonteGeneral Counsel | Stock Award(Grant) at price 0.81 per share. | 1.1K | $927 |
| Jun 1, 2025 | Domzalski David TChief Executive Officer | Stock Award(Grant) at price 0.81 per share. | 8.7K | $7.03K |
| Jan 14, 2025 | Lepore Patrick GDirector | Purchase at price 2.92 per share. | 15K | $43.80K |
| Nov 28, 2024 | Domzalski David TChief Executive Officer | Stock Award(Grant) at price 2.10 per share. | 3.9K | $8.19K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -2.4 | 6.0 | -0.3 | 6.5 | 7.1 | -4.5 | 7.6 | -5.9 | -31.7 | -17.4 | −35.9% | ||
| 2025 | -29.9 | 7.2 | -37.3 | -15.8 | -28.6 | 73.7 | -77.8 | -12.3 | 4.4 | 6.3 | 8.1 | 50.6 | −82.7% |
| 2024 | -26.6 | 30.4 | 37.7 | -17.9 | 0.8 | -22.4 | -3.6 | -4.2 | 3.3 | 44.7 | 8.8 | 13.2 | +43.8% |
| 2023 | 73.3 | -28.7 | -7.6 | 70.8 | 19.6 | -34.8 | 13.4 | -6.5 | -7.1 | -24.5 | 8.5 | -29.6 | −13.7% |
| 2022 | -39.1 | -12.7 | 19.9 | -35.4 | -3.1 | -4.4 | 11.1 | -27.5 | -28.8 | 14.8 | -9.0 | -35.6 | −85.3% |
| 2021 | 25.3 | -5.8 | -8.2 | -27.8 | -20.0 | -11.1 | -23.1 | -37.0 | -18.2 | -3.6 | -23.1 | -1.0 | −83.9% |
| 2020 | -0.9 | -35.9 | -9.2 | -32.1 | 31.3 | -27.6 | -6.9 | -5.0 | 8.5 | -3.6 | 6.3 | -7.1 | −65.9% |
| 2019 | 29.9 | 59.1 | -7.8 | -8.3 | -6.5 | -11.0 | -36.7 | 29.8 | -8.9 | 13.2 | -21.9 | 17.2 | +12.6% |
| 2018 | -6.4 | 9.1 | -78.7 | 4.5 | -3.0 | 0.5 | -5.9 | 28.3 | -38.1 | -1.5 | -31.4 | −88.8% |
Buy / hold / sell counts
Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases. The company's candidate, YB-101, is a humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor (TSHR) for the treatment of Graves' disease and thyroid eye disease. The company was incorporated in 2025 and is based in New York, New York.